NCR1 antibody

Catalog No. ABIN320360

Product Details anti-NCR1 Antibody

Target: NCR1 (Natural Cytotoxicity Triggering Receptor 1 (NCR1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This NCR1 antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Enzyme Immunoassay (EIA)

Specificity: This antibody reacts to CD335.

Purification: Protein-G affinity chromatography

Clone: N1D9

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Phosphate buffered saline, pH 7.4, containing 0.08 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Target Details for NCR1

Target: NCR1 (Natural Cytotoxicity Triggering Receptor 1 (NCR1))

Alternative Name: CD335 / NKp46 (NCR1 Products)

Synonyms: CD335 antibody, LY94 antibody, NK-p46 antibody, NKP46 antibody, Ly94 antibody, NKp46 antibody, KILR-1 antibody, Nk-p46 antibody, Nkp46 antibody, natural cytotoxicity triggering receptor 1 antibody, NCR1 antibody, Ncr1 antibody

Background: A natural cytotoxicity receptor (NCR), NKp46, is a glycoprotein that has two extracellular Ig-like domains followed by a ~40 residue stalk resion, a type I transmembrane domain, and a short cytoplasmic tail. NKp46 has been shown to represent a novel NK cell-specific molecule involved in human NK cell activation. The natural cytotoxicity receptors (NCRs) are a recently characterized family of Ig-like activation receptors that appear to be major triggering receptors in tumor cell recognition. NKp46 has been implicated in NK cell-mediated lysis of several autologous tumor cells and pathogen-infected cell lines.Synonyms: LY94, NCR1, NK cell-activating receptor, NKp46, Natural cytotoxicity triggering receptor, Natural killer cell p46-related protei

UniProt: O76036

Pathways: Regulation of Leukocyte Mediated Immunity